Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK Exits $4.2bn Cancer Drug Deal With Merck KGaA After Multiple Failures

Plug Pulled After Three Trial Flops

Executive Summary

Bintrafusp alfa was once seen as a blockbuster contender by the partners but GSK’s withdrawal narrows further its chances of success.

You may also be interested in...



Merck KGaA Health Care Head Happy With Old And New Mix

The German firm’s pharma chief Peter Guenter says that while the firm’s lifecycle management of older products is industry-leading, “innovation is the lifeblood of any pharmaceutical company," and he is confident Merck’s promising pipeline will augment its current big earners.

Merck KGaA Healthcare Head Happy With Old And New Mix

The German firm’s pharma chief Peter Guenter tells Scrip that while the firm’s lifecycle management of older products is industry-leading, “innovation is the lifeblood of any pharmaceutical company," and he is confident Merck’s promising pipeline will augment its current big earners.

AstraZeneca Pushes Into GI Cancers With HIMALAYA And TOPAZ-1

Pivotal data presented at the ASCO GI meeting in liver and biliary tract cancers could add a couple of billion dollars to Imfinzi’s sales and breathe new life into the CTL4 inhibitor tremelimumab.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC145165

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel